AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04051996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib
Description: Glasdegib will be administered at the starting dose of 100 mg orally once daily.
Study NCT04051996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be administered per local label and will be administered by IV infusion at a dose of 20 mg/m2/day for either 5 days or 10 days as determined by randomization. Each cycle will be every 28 days.
Study NCT02163538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: articulating Enseal
Description: Vessel-sealing device used for laparoscopic hysterectomy.
Study NCT02163538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure device
Description: Vessel-sealing device used for laparoscopic hysterectomy.
Study NCT01488604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymeric Nasal Spray
Description: Experimental nasal spray
Study NCT01488604 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Nasal Spray
Description: Sham nasal spray
Study NCT00894803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Description: IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
Study NCT00894803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rt-PA
Description: Intravenous recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy.
Study NCT00894803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rt-PA
Description: Intravenous recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy.
Study NCT04006288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients on aspirin and plavix will be randomized to either continue with aspirin and plavix or to switch to aspirin and rivaroxaban
Study NCT04006288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Patients on aspirin and prasugrel will be randomized to either continue with aspirin and prasugrel or to switch to aspirin and rivaroxaban
Study NCT04006288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: Patients on aspirin and ticagrelor will be randomized to either continue with aspirin and ticagrelor or to switch to aspirin and rivaroxaban
Study NCT04006288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: all patients will remain on aspirin
Study NCT04006288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: all patients will remain on aspirin
Study NCT04006288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: Patients on DAPT will be randomized to either continue with DAPT or to switch to aspirin and rivaroxaban
Study NCT01412996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: single ACCESS laparoscopic cholecystectomy
Study NCT01412996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SURGERY
Description: CONVENTIONAL LAPAROSCOPIC CGOLECYSTECTOMY
Study NCT03101280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg (equivalent to an average body weight-based dose of 15 milligrams per kilogram \[mg/kg\]) will be administered by IV infusion once every 3 weeks, corresponding to a 21-day treatment cycle. Participants will receive atezolizumab starting on Cycle 1, Day 1. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
Study NCT03101280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: The starting dosage level of rucaparib for Part 1 is 400 mg PO BID during a 21-day treatment cycle. During Part 1, the rucaparib doses were increased up to a maximum of 600 mg PO BID using a standard 3 + 3 dose escalation. RP2D was identified as 600 mg BID. During Part 2 of the study, rucaparib will be dosed at the RP2D determined in Part 1. Participants in Part 1 of the study will receive rucaparib starting on Cycle 1, Day 1. During Part 2, participants will receive rucaparib monotherapy during a 21-day run-in period. After completion of the rucaparib run-in period and the first on-treatment biopsy between Days 15 and 21 of the run-in period, participants will begin Cycle 1, Day 1 of the rucaparib. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
Study NCT04871906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercises
Description: Our interventions are home-based stretching exercises. The experimental group will receive 6 stretching exercises which stretch 20-30 seconds, relax for 10 seconds, and repeat 5 times for each side. It will take 25-30 minutes every day for continuous 8 weeks. Those include stretching of the deep front line, spiral line, superficial front line, lateral line, superficial back line, and plantar flexors. Designed concepts are the following three: 1) based on ''Anatomy- Train'' theory, 2) emphasize on movements of trunk and pelvis, and 3) stress on the stretching of lower extremities.
Study NCT00965601 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Subjects randomized to the Active Arm will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
Study NCT01651728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Tablet 20 mg once daily for 30 days
Study NCT01651728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily for 30 days
Study NCT01821079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)
Study NCT01821079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
Study NCT03587376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atabecestat
Description: Blood samples will be collected from participants previously treated with atabecestat.
Study NCT03587376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atabecestat
Description: Blood samples will be collected from participants previously treated with atabecestat.
Study NCT04554784 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Patients' condition will be continue managed by pain specialists with regular follow-ups and continue patients' active concurrent pain treatment such as taking analgesics, physiotherapy, massage, chiropractor.
Study NCT04554784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bowen
Description: Patients will be referred to Occupational therapist for Bowen Therapy. There will be a week washout period before the start of Bowen Therapy. During a week washout period and study period, patients can continue taking analgesia, but advised to stop the concurrent treatments which can affect the deep tissue such as massage, physiotherapy, and chiropractic to minimize the counteracting effect on the Bowen's action.~During a Bowen Therapy session, patients will lie relaxed on the examination couch wearing loosely fitting clothing or only the affected area being exposed. The therapist applies a series of gentle movements across the body. The gentle movements focus on a body of muscle, tendon or nerve and release tension through the nerve within the area. Each session will last for 30 minutes to an hour. After each session, the next appointment will be given to patients. The first four sessions will be scheduled on weekly basis, and the remaining four on biweekly session.
Study NCT02641925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Omentum preserving
Description: The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed during gastrectomy with lymph node dissection.
Study NCT02641925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total omentectomy
Description: Whole omentum will be removed during gastrectomy with lymph node dissection.
Study NCT00449696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gel-200
Description: Single intra-articular injection
Study NCT00449696 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intra-articular injection
Study NCT00711698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Description: Patients in this arm will be treated with a bolus of narcotic followed by PCA
Study NCT00711698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nurse-administered intermittent IV bolus opioid therapy (NAIBOD)
Description: In this arm patients will receive the current standard of care of IV bolus narcotic therapy
Study NCT01205217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib 1000 mg orally once daily continuously
Study NCT01205217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Part II (Week 13-24) Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week
Study NCT01205217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days
Study NCT01205217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days
Study NCT01205217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part I (Week 1-12) Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days
Study NCT01205217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Part I (Week 1-12) Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days
Study NCT01205217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week
Study NCT01205217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week
Study NCT02356458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Combination therapy:~Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Ibrutinib: p.o daily; Phase I: according to DL; Phase II: RP2D established in phase I~Maintenance therapy:~p.o daily: 560 mg
Study NCT02356458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Combination therapy:~Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Injection of Bortezomib (s.c.), dose of 1.3 mg/m2 on day 1, 4, 8, 11
Study NCT01026844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Taken orally once a day
Study NCT01026844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: Taken orally once a day
Study NCT03322956 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physioterapy intervention
Description: In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®.
Study NCT03322956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physioterapy intervention
Description: In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®.
Study NCT01446159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573
Description: Intravenous infusion of MEDI-573 (10 or 30 or 45 mg/kg) will be administered on Day 1 of each 21-day cycle until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
Study NCT01446159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
Study NCT02890797 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiology
Description: The investigators propose to performed a chest ultrasound in infants (\<24 months) admitted for bronchiolitis with an available chest X-ray
Study NCT03631485 — intervention group
Intervention type: OTHER
Intervention: Exposure_having children with cancer
Description: No intervention. The exposure is having children with cancer.
Study NCT04712188 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Musculoskeletal ultrasonography
Description: The ultrasonographic assesment will be used to examine the supraspinatus tendon thickness, the long head of the biceps brachii tendon thickness and acromio-humeral distance before and after wheelchair propelling test.
Study NCT04712188 — intervention group
Intervention type: OTHER
Intervention: Wheelchair propelling test
Description: Participants will use their own wheelchairs with their preferred stroke pattern for 20 minutes at a speed of 1 m / s on a motorized treadmill for a wheelchair propelling test. Wheelchair propelling videos will be recorded during the test. Shoulder kinematics will be analyzed using Kinovea motion analysis software and stoke pattern will be confirmed
Study NCT04731636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thoracoabdominal aortic stent system
Description: Patients who meet all inclusion criteria and don't meet any exclusion criteria were implanted with thoracoabdominal aortic stent system.
Study NCT03874546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: * Two clinicians will complete a questionnaire that analyses their perception of the patient's prognosis at Day1 and Day7.~* At 6 months, another clinician will establish the patient prognosis using Glasgow Outcome Scale and Glasgow outcome scale extended. This clinician must not know the patient's IMPACT score and prognosis established at Day 1 and Day 7. His evaluation will be compare to the patient's prognosis established previously (Day1 and Day7).
Study NCT03523819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1002
Description: Dose levels will be escalated following a modified 3+3 dose escalation scheme
Study NCT03523819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1003
Description: Fixed dose at 200mg in combination with CS1002 on a specified dose level
Study NCT03566602 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dura Sealant Patch
Description: Adjunctive bioresorbable patch
Study NCT04500366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socialization
Description: Social interaction is associated with better mental and physical health, and evidence suggests that group versus individual engagement may offer unique cognitive benefits for older adults as well as peer reinforcement and encouragement.
Study NCT04500366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Socialization
Description: Social interaction is associated with better mental and physical health, and evidence suggests that group versus individual engagement may offer unique cognitive benefits for older adults as well as peer reinforcement and encouragement.
Study NCT04500366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Group Exercise
Description: Participants will receive twice-weekly (one hour per class) virtual exercise via small-group physiotherapy sessions for a total of 12 weeks. All exercise sessions will occur virtually via a videoconferencing system. The classes will focus on functional movements specifically designed for seniors with frailty and mobility challenges, and will include modifications for gait aids such as canes or walkers. Class sizes will be small to allow for tailoring of exercises based on challenging, safe, progressive, evidence-based exercises. In accordance with recent guidelines to achieve 3 hours/week for fall prevention practice in older adults, participants will also be provided with tailored supplemental home exercises developed by the study physiotherapist to gain an additional 1 hour of physical activity.
Study NCT04500366 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nutrition Consult and Protein Supplementation
Description: Nutrition Consult: Participants will be scheduled for a one-on-one virtual nutrition consult. During the consultation, study staff will assess the nutritional status of the participant and will provide them with counselling and coaching to improve their nutrition.~Protein Supplementation: Oral nutrition supplements commercially available from Nestle will be provided unless contraindicated. The oral nutrition supplement contains 360 calories and 14 grams of protein per serving. Participants are advised to take this with a meal or within 3 hours of exercise on activity days.
Study NCT04500366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Review
Description: A study pharmacist will review the participant's medication list and will utilize Beers and/or START/STOPP criteria to provide recommendations to optimize/update their medications to the participant's healthcare provider. Study geriatricians will be listed as contacts on the primary care provider recommendations and available for consultation.
Study NCT00278577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Ablation and Hematopoietic Stem Cell Support
Description: Autologous Hematopoietic Stem Cell Transplant
Study NCT03396796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagus nerve-preserving group
Description: The modified vagus nerve-preserving procedure was performed in the following order: (1) left gastroepiploic vein along greater curvature; (2) the posterior surface of stomach, including the posterior gastric veins; (3) the left lateral surface of the distal esophagus; (4) the left inferior phrenic veins; (5) the posterior surface of the distal esophagus;(6) the anterior surface of the distal esophagus; and (7) the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved. the adherent junction between visceral peritoneum and the right crural diaphragm, and divided it into the lesser omental sac. The left gastric artery and vein and the posterior gastric veins were transected en bloc using a linear laparoscopic vascular stapler.
Study NCT03817164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autonomic Nerve Modulation - Active
Description: Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
Study NCT03817164 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Autonomic Nerve Modulation - Control
Description: Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
Study NCT00005780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH-R
Description: EPOCH-R for 6 cycles
Study NCT00005780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) monthly with the vaccine for 5 doses
Study NCT00005780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Idiotype vaccine
Description: 1 injection of vaccine monthly for 5 doses
Study NCT03186300 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PEPPER system
Description: In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
Study NCT01938079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be initiated as a one-time 40 mg bolus of ketamine followed by a continuous intravenous infusion of 5 micrograms/kg/min at the start of ECMO.
Study NCT01938079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedative drug regimen
Description: (Standard of Care) Fentanyl or hydromorphone and midazolam infusions will be administered to all patients and titrated at the discretion of the attending physician to maintain the desired level of sedation.